Sign In
Buy FATE
$2.22
-0.350 (-13.62%)
At Close: Jun 03, 2026
Sumitomo Mitsui Trust Holdings Inc. Has $18.26 Million Position in Fate Therapeutics Inc (NASDAQ:FATE)
06:42am, Tuesday, 04'th Aug 2020
Sumitomo Mitsui Trust Holdings Inc. lessened its stake in shares of Fate Therapeutics Inc (NASDAQ:FATE) by 42.5% during the second quarter, according to its most recent filing with the Securities & Ex
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2020 Financial Results
08:01pm, Wednesday, 29'th Jul 2020
SAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for
Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term Players
06:38pm, Tuesday, 28'th Jul 2020
47.6% single-year revenue increase on the guidance of an additional 15% sales growth in 2021. 67% capital gains YoY with a 4% downside risk in the same period.
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
04:32pm, Tuesday, 28'th Jul 2020
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Could Fate Therapeutics Be a Millionaire-Maker Stock?
11:40am, Sunday, 26'th Jul 2020
Thanks to its powerful platform that enables the efficient mass production of high-impact and high-complexity cellular therapies for cancers and immune disorders, its manufacturing technology licensin
Vident Investment Advisory LLC Sells 32,314 Shares of Fate Therapeutics Inc (NASDAQ:FATE)
06:22am, Wednesday, 22'nd Jul 2020
Vident Investment Advisory LLC lessened its position in Fate Therapeutics Inc (NASDAQ:FATE) by 42.0% during the second quarter, according to the company in its most recent Form 13F filing with the Sec
2 Stocks to Hold for the Next 20 Years
12:11pm, Tuesday, 21'st Jul 2020
Two decades is a long time, but these up-and-coming biopharma companies could earn significantly larger valuations in that span.
Were Hedge Funds Right About Piling Into Fate Therapeutics Inc (FATE)?
03:06pm, Thursday, 16'th Jul 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
Analysts Anticipate Fate Therapeutics Inc (NASDAQ:FATE) Will Announce Quarterly Sales of $20.33 Million
05:02am, Thursday, 16'th Jul 2020
Brokerages expect that Fate Therapeutics Inc (NASDAQ:FATE) will post $20.33 million in sales for the current quarter, according to Zacks. Nine analysts have provided estimates for Fate Therapeutics’
License Covers First-in-class Alloimmune Defense Receptors Designed to Protect Allogeneic Cells from Rejection in Immunocompetent Recipients Preclinical Data Published in the Journal Nature Biotechno
Axa Purchases Shares of 25,900 Fate Therapeutics Inc (NASDAQ:FATE)
06:34am, Sunday, 12'th Jul 2020
Axa purchased a new position in Fate Therapeutics Inc (NASDAQ:FATE) in the first quarter, HoldingsChannel reports. The institutional investor purchased 25,900 shares of the biopharmaceutical company�
Fate's IND Application for CAR T Cell Therapy Gets FDA Nod
02:18pm, Friday, 10'th Jul 2020
Fate (FATE) obtains FDA clearance for its IND application for FT819, targeting CD19+ malignancies.
Fate Therapeutics Announces FDA Clearance of IND Application for First-ever iPSC-derived CAR T-Cell Therapy
12:00pm, Thursday, 09'th Jul 2020
FT819 CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus Phase 1 Clinical Study will Evaluate FT819.
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For Bankruptcy
12:00am, Wednesday, 08'th Jul 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 7)
AbbVie Inc (NYSE: ABBV)...
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 6)
ACADIA Pharmaceuticals Inc...
